Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2004

View Archived Issues

Wyeth to manufacture Herceptin for Genentech

Preliminary results from phase II study of Furosemide GR

Nastech and Merck & Co form alliance over PYY3-36 Nasal Spray

Two series of anti-HIV CCR5 antagonists reported by Takeda

Kissei scientists prepare ZAP-70 and Syk kinase inhibitors for use in immune disorders

New MCH-1R antagonists and their use in obesity, diabetes, etc.

BCRP inhibitors and their use as drug resistance modulators described by Yakult Honsha

Novel muscarinic M4 agonists with potential in schizophrenia therapy

Ono presents new prostanoid EP3 antagonists and their use in pain and other disorders

Teijin patent covers new vitamin D analogues for bone disorders

Novel antibacterial carbapenems prepared and evaluated by Meiji Seika team

Discovery of inhibitors of the MDM-p53 protein-protein interaction

Apoptosis inducer shows promise in phase I trial in cancer patients

In vitro and in vivo activity of small-molecule HDAC inhibitor

Orphan drug designation gives Gliadel exclusivity to 2010

Desilux enters phase III program for atopic dermatitis

Pharmacopeia delivers leads in Neurocrine collaboration

Palladone extended-release capsules approved for persistent pain

Statins show antiproliferative effects on pancreatic adenocarcinoma

CombinatoRx and ABC2 establish brain cancer collaboration

Preliminary data reported from phase I trial of antiangiogenic peptide

BioMedicines changes name to Intarcia Therapeutics

Schwarz launches Parcopa

IL-2 does not influence pharmacokinetics of CNTO-328 in monkeys

Preliminary data support the use of AGI-1067 in coronary atherosclerosis

European approval for Raptiva for psoriasis

Full enrollment reached in phase II trial of CYT002-NicQb

European CHMP gives positive opinion for extension of indication for Pegasys

Extension of indication recommended for Taxotere in E.U.

New targeted delivery methodology for male contraception

mGlu4 receptor modulator has anxiolytic-like effects

Visilizumab mechanism, clinical benefit investigated

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...